Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer

Abstract Background Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However, the FN occurs less frequently when the dose of DTX is reduced because of other...

Full description

Bibliographic Details
Main Authors: Kosuke Hamai, Shinya Miyaka, Shinpei Tada, Suguru Fujita, Tetsu Hirakawa, Mirai Matsumura, Sayaka Ueno, Takuya Tanimoto, Nobuhisa Ishikawa
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Reports
Subjects:
docetaxel
febrile neutropenia
pegfilgrastim
ramucirumab
Online Access:https://doi.org/10.1002/cnr2.1793

Internet

https://doi.org/10.1002/cnr2.1793

Similar Items